Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study
- 8 January 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 118 (1) , 73-82
Abstract
Rationale:: Low high-density lipoprotein-cholesterol (HDL-C) in patients with coronary heart disease (CHD) may be caused by rate-limiting amounts of lecithin:cholesterol acyltransferase (LCAT). Raising LCAT may be beneficial for CHD, as well as for familial LCAT deficiency, a rare disorder of low HDL-C. Objective:: To determine safety and tolerability of recombinant human LCAT infusion in subjects with stable CHD and low HDL-C and its effect on plasma lipoproteins. Methods and Results:: A phase 1b, open-label, single-dose escalation study was conducted to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human LCAT (ACP-501). Four cohorts with stable CHD and low HDL-C were dosed (0.9, 3.0, 9.0, and 13.5 mg/kg, single 1-hour infusions) and followed up for 28 days. ACP-501 was well tolerated, and there were no serious adverse events. Plasma LCAT concentrations were dose-proportional, increased rapidly, and declined with an apparent terminal half-life of 42 hours. The 0.9-mg/kg dose did not significantly change HDL-C; however, 6 hours after doses of 3.0, 9.0, and 13.5 mg/kg, HDL-C was elevated by 6%, 36%, and 42%, respectively, and remained above baseline ≤4 days. Plasma cholesteryl esters followed a similar time course as HDL-C. ACP-501 infusion rapidly decreased small- and intermediate-sized HDL, whereas large HDL increased. Pre–β-HDL also rapidly decreased and was undetectable ≤12 hours post ACP-501 infusion. Conclusions:: ACP-501 has an acceptable safety profile after a single intravenous infusion. Lipid and lipoprotein changes indicate that recombinant human LCAT favorably alters HDL metabolism and support recombinant human LCAT use in future clinical trials in CHD and familial LCAT deficiency patients. Clinical Trial Registration:: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01554800.Keywords
This publication has 37 references indexed in Scilit:
- LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 IndividualsThe Journal of Clinical Endocrinology & Metabolism, 2012
- Effect of Recombinant Human Lecithin Cholesterol Acyltransferase Infusion on Lipoprotein Metabolism in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2010
- High Pre-β1 HDL Concentrations and Low Lecithin: Cholesterol Acyltransferase Activities Are Strong Positive Risk Markers for Ischemic Heart Disease and Independent of HDL-CholesterolClinical Chemistry, 2010
- The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In VivoCirculation, 2009
- The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosisJournal of Lipid Research, 2009
- Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesionsGene Therapy, 2009
- Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patientsExperimental & Molecular Medicine, 2009
- Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans?Journal of Lipid Research, 2006
- Increased plasma HDL cholesterol levels and biliary cholesterol excretion in hamster by LCAT overexpressionFEBS Letters, 2004